NBW Capital LLC Sells 351 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

NBW Capital LLC lessened its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 20,238 shares of the pharmaceutical company’s stock after selling 351 shares during the period. Vertex Pharmaceuticals comprises 1.5% of NBW Capital LLC’s investment portfolio, making the stock its 25th biggest position. NBW Capital LLC’s holdings in Vertex Pharmaceuticals were worth $8,150,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of VRTX. Dunhill Financial LLC raised its position in Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 24 shares during the last quarter. Brown Lisle Cummings Inc. bought a new position in Vertex Pharmaceuticals in the 4th quarter worth approximately $30,000. Legacy Investment Solutions LLC bought a new position in Vertex Pharmaceuticals in the 3rd quarter worth approximately $33,000. Truvestments Capital LLC bought a new position in Vertex Pharmaceuticals in the 3rd quarter worth approximately $35,000. Finally, Sugar Maple Asset Management LLC bought a new position in Vertex Pharmaceuticals in the 4th quarter worth approximately $35,000. Institutional investors own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 310 shares of the firm’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total value of $142,547.30. Following the completion of the transaction, the executive vice president now directly owns 64,021 shares of the company’s stock, valued at approximately $29,438,776.43. This trade represents a 0.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 1,084 shares of company stock valued at $505,512 in the last ninety days. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Price Performance

Shares of VRTX opened at $483.31 on Tuesday. The stock has a market capitalization of $124.11 billion, a P/E ratio of -219.69, a P/E/G ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.85 and a twelve month high of $519.88. The company has a 50 day moving average of $441.95 and a 200-day moving average of $461.06. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

VRTX has been the subject of several research analyst reports. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Piper Sandler reduced their price target on Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Scotiabank lifted their price objective on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a “sector perform” rating in a research note on Tuesday, February 11th. Truist Financial increased their target price on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Finally, BMO Capital Markets set a $545.00 target price on Vertex Pharmaceuticals in a research report on Friday, January 31st. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $506.70.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.